Every Form 4 that AngioDynamics, Inc. (ANGO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ANGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANGO filings page.
AngioDynamics Inc. executive Warren Nighan Jr., SVP Quality and Regulatory, reported the sale of 23,370 shares of common stock on 2026-07-30. The reported price of $14.72 per share is a weighted average from multiple trades between $14.65 and $14.80. After this transaction, he directly holds 64,745 shares. The filing indicates the sale was not made under a Rule 10b5-1 trading plan.
AngioDynamics Inc. executive Laura Piccinini, SVP International, reported vesting of performance share units granted on July 19, 2023. A target grant of 28,336 units resulted in 8,047 common shares being issued, while 4,506 shares were withheld at $13.82 per share for taxes and the remaining units were forfeited.
Warren Nighan Jr., SVP Quality and Regulatory at AngioDynamics, had a 2023 performance share unit grant settle. A target award of 20,052 performance share units led to the issuance of 5,694 shares of common stock based on performance, with the remaining units forfeited. Of the shares issued, 1,671 were withheld at $13.82 per share to satisfy tax withholding obligations.
AngioDynamics Inc EVP and CFO Stephen A. Trowbridge reported equity award activity related to performance share units granted on July 19, 2023. Based on performance metrics and relative total shareholder return, 16,296 shares of Common Stock vested and were issued from a 57,381-unit target grant, with the remaining units forfeited. To satisfy related tax withholding obligations, 8,319 shares were withheld at $13.82 per share.
AngioDynamics Inc. President and CEO James C. Clemmer reported the vesting and settlement of a performance share grant on July 22, 2026. A 2023 target grant of 184,361 performance share units was settled based on multi-year performance, resulting in issuance of 52,358 shares of Common Stock and forfeiture of the remaining units. Of the issued shares, 26,728 were disposed of at $13.8200 per share to satisfy tax withholding obligations, with the balance retained as directly owned common stock.
Chad Thomas Campbell, SVP/GM Vascular Access at AngioDynamics, reported the vesting of 6,466 shares of Common Stock on July 22, 2026, from performance share units granted July 19, 2023. A target of 22,768 performance share units could pay out 0–200%, with an additional 20% adjustment tied to relative total shareholder return over fiscal years 2024–2026; unearned units were forfeited. To cover tax withholding on the vesting, 2,330 shares were disposed at $13.82 per share.
REED JAN STERN reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. director Jan Stern Reed received a grant of 11,887 shares of common stock on July 15, 2026, reported at a price of $0.00 per share. A footnote explains this represents 11,887 restricted stock units granted as regular annual compensation for board service that immediately vested at grant. Following this award, Reed directly holds 116,921 common shares.
Licitra Karen A reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. director Karen A. Licitra received a grant of 11,887 shares of common stock on July 15, 2026, representing 11,887 restricted stock units as regular annual compensation for board service. These units immediately vested at grant, increasing her direct holdings to 102,322 shares.
JOHNSON WESLEY reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. director Wesley Johnson received a grant of 11,887 shares of common stock in the form of restricted stock units on 2026-07-15 as regular annual compensation for board service. The units immediately vested, bringing his directly held common shares to 155,425.
DONNELLY HOWARD W reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc director Howard W. Donnelly received a grant of 11,887 shares of common stock on July 15, 2026, representing 11,887 restricted stock units granted as regular annual compensation for board service. These units vested immediately, increasing his directly held common stock to 178,938 shares.
Burgess Lorinda reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics director Lorinda Burgess received an equity award of 11,887 restricted stock units as regular annual compensation for board service on July 15, 2026. These RSUs immediately vested at grant, increasing her directly held common stock to 67,144 shares. The award was a no-cost stock grant and was not made under a Rule 10b5-1 trading plan.
AngioDynamics Inc director Auen Eileen O'Shea reported the acquisition of 11,887 shares of common stock, representing 11,887 restricted stock units granted as regular annual compensation for board service. These units vested immediately at grant, bringing her direct holdings to 116,605 shares of AngioDynamics common stock.
Tarnoff Michael E reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics director Michael E. Tarnoff received a grant of 11,887 shares of common stock on July 15, 2026, representing restricted stock units granted as regular annual director compensation that immediately vested at grant. After this award, he directly holds 95,265 common shares, and the transaction was not made under a Rule 10b5-1 trading plan.
Trowbridge Stephen A reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics EVP and CFO Stephen A. Trowbridge received equity awards on July 15, 2026. He was granted 53,257 restricted stock units, vesting in four equal annual installments each July 15 from 2027 through 2030, and 53,257 performance rights, each a contingent right to one share of common stock. Payout on the performance rights can range from 0% up to 240% of the target, based on relative total shareholder return over a three-year performance period. After the restricted stock unit award, his directly held common stock reported in this line totals 297,819 shares.
Piccinini Laura reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. senior vice president of international operations Laura Piccinini received equity awards on July 15, 2026. She was granted 19,860 restricted stock units, each representing a contingent right to one common share, vesting in four equal annual installments from July 15, 2027 through July 15, 2030, bringing her direct common stock holdings to 78,388 shares. She also received 19,860 performance rights, each tied to one share of common stock, with between 0% and 200% of the target amount earned over a three-year period and a potential 20% adjustment, for a maximum payout of up to 240% of the target based on total shareholder return relative to a peer group.
Nighan Warren JR reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. reported that SVP Quality and Regulatory Warren Nighan Jr. received equity awards on July 15, 2026. He was granted 17,966 restricted stock units, vesting in four equal annual installments from July 15, 2027 through 2030, and 17,966 performance rights tied to three-year relative total shareholder return. Following the RSU grant, he directly holds 84,092 shares of common stock.
AngioDynamics Inc. reported that officer Chad Thomas Campbell, SVP/GM Vascular Access, received equity awards on July 15, 2026. He acquired 16,081 restricted stock units, each convertible into one share of common stock, vesting in four equal annual installments on July 15 of 2027, 2028, 2029 and 2030. He also received 16,081 performance rights, each representing a contingent right to one share, with 0–200% of the target (plus a possible 20% adjustment, for up to 240% of target) earned based on three-year total shareholder return relative to a peer group. Following these grants, he directly held 104,540 shares of common stock.
Weiss Lawrence T reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics SVP and Chief Legal Officer Lawrence T. Weiss received equity-based compensation on July 15, 2026. He was granted 21,288 restricted stock units, each representing a contingent right to one share of common stock, plus 21,288 performance rights, also initially tied one-for-one to common shares.
The restricted stock units vest in four equal annual installments on July 15 of 2027, 2028, 2029 and 2030. The performance rights are earned over a three-year performance period based on total shareholder return versus a peer group, with a potential payout from 0% up to 240% of the 21,288-share target; any unearned awards are forfeited. Following these grants, Weiss directly holds 112,618 shares of common stock.
AngioDynamics Inc. executive Lawrence T. Weiss, SVP and Chief Legal Officer, reported an exempt disposition of 2,267 shares of common stock on July 16, 2026. The shares were withheld at $14.14 per share to satisfy tax obligations from vesting restricted stock units granted July 16, 2025, leaving 91,330 shares held directly.
AngioDynamics EVP and CFO Stephen A. Trowbridge reported tax-related share withholdings tied to restricted stock unit vesting. On July 16, 17 and 20, 2026, a total of 12,067 common shares were disposed of at $14.14, $13.51 and $13.71 per share, respectively, to satisfy tax withholding obligations on RSUs granted in 2025, 2024 and 2022. The filing indicates these exempt dispositions were not made under a Rule 10b5-1 trading plan.
AngioDynamics Inc. executive Laura Piccinini, SVP International, reported three exempt dispositions of common stock on July 16, 17 and 20, 2026, totaling 8,228 shares, to satisfy tax withholding obligations on pre-determined vesting of restricted stock units granted on July 16, 2025, July 17, 2024 and July 20, 2022.
AngioDynamics Inc. reports that SVP Quality and Regulatory Warren Nighan Jr. had a total of 3,777 common shares withheld in three exempt dispositions on July 16, 17 and 20, 2026, at prices from $13.51 to $14.14 per share to satisfy tax withholding obligations tied to pre-determined vesting of previously granted restricted stock units. These events were not designated as occurring under a Rule 10b5-1 trading plan.
AngioDynamics Inc. President and CEO James C. Clemmer reported five exempt dispositions of common stock from July 16–20, 2026. In total, 45,711 shares were withheld at per-share prices including $14.1400, $13.5100, and $13.7100 to satisfy tax withholding obligations on previously granted restricted stock units as they vested.
AngioDynamics Inc. executive Chad Thomas Campbell, SVP/GM Vascular Access, reported tax-related dispositions totaling 3,838 shares of common stock. On July 16, 17, and 20, 2026, shares were withheld at $14.14, $13.51, and $13.71 per share to satisfy tax withholding obligations from pre-determined vesting of restricted stock units granted in 2025, 2024, and 2022.
AngioDynamics (ANGO) reported an insider open‑market purchase. On 10/21/2025, an officer serving as SVP, Chief Legal Officer bought 10,000 shares of common stock, coded “P” for purchase. The weighted average price was $11.81, with trades executed between $11.71 and $11.90. After this transaction, the reporting person beneficially owned 93,597 shares, held directly. The filing notes the weighted‑average pricing and that detailed trade‑by‑trade data within the price range is available upon request.